Dechra Pharmaceuticals (BATS-CHIXE:DPHL) - Hisse Senedi Fiyatı, Haberler ve Analizler

DPHL Stoklara Genel Bakış

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Daha fazla detay

DPHL temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Kazançların yılda 62.48% oranında artması öngörülüyor

Risk Analizi

Faiz ödemeleri kazançlarla iyi karşılanmıyor

Dechra Pharmaceuticals PLC Rakipler

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Indivior

LSE:INDV

UK£1.1b

GSK

LSE:GSK

UK£54.6b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Dechra Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£38.70
52 Haftanın En Yüksek Seviyesi	UK£38.84
52 Haftanın En Düşük Seviyesi	UK£24.74
Beta	0.78
11 Aylık Değişim	0.55%
3 Aylık Değişim	2.27%
1 Yıllık Değişim	35.79%
33 Yıllık Değişim	5.91%
5 Yıllık Değişim	63.71%
Halka arzdan bu yana değişim	744.98%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	DPHL	GB Pharmaceuticals	GB Pazar
7D	0.2%	4.2%	1.7%
1Y	35.8%	3.0%	8.4%

Getiri vs. Endüstri: DPHL geçen yıl % 3 oranında getiri sağlayan UK Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: DPHL geçen yıl % 8.4 oranında getiri sağlayan UK Piyasasını aştı.

Fiyat Oynaklığı

Is DPHL's price volatile compared to industry and market?
DPHL volatility
DPHL Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: DPHL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: DPHL 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 6% dan 1% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC Temel Bilgiler Özeti

Dechra Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DPHL temel i̇stati̇sti̇kler
Piyasa değeri	UK£4.40b
Kazançlar(TTM)	-UK£27.90m
Gelir(TTM)	UK£761.50m

5.8x

P/S Oranı

-157.8x

F/K Oranı

DPHL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DPHL gelir tablosu (TTM)
Gelir	UK£761.50m
Gelir Maliyeti	UK£331.90m
Brüt Kâr	UK£429.60m
Diğer Giderler	UK£457.50m
Kazançlar	-UK£27.90m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.24
Brüt Marj	56.42%
Net Kâr Marjı	-3.66%
Borç/Özkaynak Oranı	64.6%

DPHL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

DPHL Stoklara Genel Bakış

Ödüller

Risk Analizi

Dechra Pharmaceuticals PLC Rakipler

LSE:HIK

UK£4.4b

AIM:HCM

UK£2.4b

LSE:INDV

UK£1.1b

LSE:GSK

UK£54.6b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Dechra Pharmaceuticals PLC Temel Bilgiler Özeti

5.8x

-157.8x

Kazanç ve Gelir